Adaptive Biotechnologies Corp., which trades under the ticker ADPT on NASDAQ, recently disclosed a transaction involving its Chief Financial Officer, Kyle Piskel. According to an SEC filing, Mr. Piskel disposed of shares of the company’s common stock on May 18, 2026.
The specifics of this sale indicate that 3,115 shares were sold at a price point of $13.04 per share, resulting in total proceeds of $40,619. The filing included a crucial footnote detailing the nature of this transaction: it was executed solely to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). This process is mandated by Adaptive Biotechnologies’ established equity incentive plans and constitutes a 'sell to cover' procedure, meaning the sale did not reflect any discretionary trading choice made by Mr. Piskel.
Following this specific transaction, records indicate that Mr. Piskel maintained a direct holding of 256,725 shares of Adaptive Biotechnologies common stock. The company’s current market price is noted at $13.95, representing an increase of nearly 50% over the past year's performance. However, while the stock has shown significant appreciation, analysis from InvestingPro suggests that the share valuation may be considered elevated relative to the company's calculated Fair Value.
Beyond the insider transaction details, recent corporate filings highlight strong operational and financial developments for Adaptive Biotechnologies. The company announced impressive results for its first quarter of 2026. In this period, the reported revenue reached $70.9 million, substantially surpassing the forecasted amount of $60.89 million. This performance represents an over-performance margin of approximately 16.4% against expectations.
The primary driver behind this robust financial showing was identified as accelerated growth within Adaptive Biotechnologies’ Minimal Residual Disease (MRD) business segment. These recent developments are noted to reflect the company's continued upward momentum and market positioning. The strong revenue performance has, in turn, garnered attention from both investors and industry analysts.
In terms of broader financial metrics, the firm reported $295 million in total revenue over the trailing twelve months (TTM), demonstrating an impressive year-over-year growth rate of 56%. Despite this significant top-line expansion, the company is currently operating at a loss and remains unprofitable.
While no recent analyst upgrades or downgrades have been reported for Adaptive Biotechnologies to date, the consistent demonstration of strong earnings performance is considered noteworthy within the current market environment. These combined factors underscore Adaptive Biotechnologies' established standing within its specific sector.
The stock’s trading data shows a closing price at 13.95 USD and an after-hours movement of 14.23 USD, indicating recent volatility in pricing action. The comprehensive nature of the financial reporting, including details on valuation models and historical performance, allows investors to gain deeper insights into ADPT's overall financial health and potential for future growth.